Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 29:2013:458353.
doi: 10.1155/2013/458353. eCollection 2013.

Should Finasteride Be Routinely Given Preoperatively for TURP?

O M Aboumarzouk  1 , M Z Aslam, A Wedderburn, K Turner, O Hughes, H G Kynaston
Affiliations

Should Finasteride Be Routinely Given Preoperatively for TURP?

O M Aboumarzouk et al. ISRN Urol. .

Abstract

Objective. The aim of the review was to compare the use of finasteride to placebo in patients undergoing TURP procedures. Material & Methods. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966-November 2011), EMBASE (1980-November 2011), CINAHL, Clinicaltrials.gov, Google Scholar, reference lists of articles, and abstracts from conference proceedings without language restriction for studies comparing finasteride to placebo patients needing TURPs. Results. Four randomised controlled trials were included comparing finasteride to a placebo. A meta-analysis was not conducted due to the disparity present in the results between the studies. Three of the studies found that finasteride could reduce either intra- or postoperative bleeding after TURP. One study found finasteride to significantly lower the microvessel density (MVD) and vascular endothelial growth factor (VEGF). None of the studies reported any long-term complications related to either the medication or the procedure. Conclusion. finasteride reduces bleeding either during or after TURP.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart for article selection process of the review.
See this image and copyright information in PMC

References

    1. Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU International. 2005;96(9):1319–1322. - PubMed
    1. Häggström S, Tørring N, Møller K, et al. Effects of finasteride on vascular endothelial growth factor—a placebo-controlled randomized study in BPH patients. Scandinavian Journal of Urology and Nephrology. 2002;36(3):182–187. - PubMed
    1. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. Journal of Urology. 1995;154(5):1779–1782. - PubMed
    1. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism. 1992;74(3):505–508. - PubMed
    1. Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. Journal of Urology. 2003;169(1):20–23. - PubMed

LinkOut - more resources